Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for Glioblastoma

2 Dec 2021

Abstract excerpt

Li Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome caused by germline mutations in TP53. TP53 is the most common mutated gene in human cancer, occurring in 30-50% of glioblastomas (GBM). Here, we highlight a precision medicine platform to identify potential targets for a GBM patient with LFS. We used a comparative transcriptomics approach to identify genes that are uniquely overexpressed in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Glioma Diagnosis and Treatment
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34943910
DOI: 10.3390/cells10123400

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for GlioblastomaPMID 34943910Read ↗

A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.Semantic proximity Read ↗

Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma.Semantic proximity Read ↗

A Functional Precision Oncology Approach to Identify Treatment Strategies for Myxofibrosarcoma Patients.Semantic proximity Read ↗

The Precision Oncology Approach to Molecular Cancer Therapeutics Targeting Oncogenic Signalling Pathways Is a Means to an EndSemantic proximity Read ↗

Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivitySemantic proximity Read ↗

A single-cell based precision medicine approach using glioblastoma patient-specific modelsSemantic proximity Read ↗

Functional Precision Oncology: The Next Frontier to Improve Glioblastoma Outcome?Semantic proximity Read ↗

Integrative omics analyses broaden treatment targets in human cancer.Semantic proximity Read ↗

Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicineSemantic proximity Read ↗

Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumorsSemantic proximity Read ↗

Precision oncology based on omics data: The NCT Heidelberg experienceSemantic proximity Read ↗

Pathway-centric multi-omics and functional precision medicine reveal shared drug vulnerabilities in heterogeneous adult Wilms tumorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.